kpti came out with decent data in terms of a lymphoma study or you wait for earnings or get in front, understanding that's a bit of a loaded question >> it's tough to say the stock is already down so much this is actually a product story. there is revenue here. this is an oncology company that's launching a drug into a pretty big market. they're looking at earlier lines of therapy for various lymphoma treatments there's a sarcoma pipeline here. there is something here to back up the valuation, unlike so many of these high flyers that are pretty much dream stocks or concept stocks ktpi does have real revenue and will have earnings at some point and does have a pipeline that risky a bet, the bye side doesn't typically love these new launch stories, because they tend to be -- you know, they're fairly volatile in terms of their reaction, and also, you know, given the fact that the company launched the drug during covid, it hasn't been can great for them or many other companies in the sector that introduce new drugs in a pandemic. it's tough to know do you buy it now, buy it subsequent to